Nasopharyngeal Cancer Clinical Trial
Official title:
A Multi-Center Phase II Trial of Capecitabine (Xeloda) in Combination With Cisplatin as First Line Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma
This study will evaluate the efficacy, safety, tolerability, and effect on quality of life of oral capecitabine in combination with intravenous (IV) cisplatin in participants with metastatic nasopharyngeal cancer. Participants will receive up to 8 cycles of capecitabine treatment, and cisplatin will be administered on the first day of each cycle. The anticipated time on study treatment is up to 24 weeks, and the target sample size is 44 individuals.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00370890 -
A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
|
Phase 3 | |
| Recruiting |
NCT04340024 -
Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
|
||
| Completed |
NCT00697619 -
To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
|
Phase 2 | |
| Completed |
NCT00078546 -
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)
|
Phase 1 | |
| Recruiting |
NCT04453826 -
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
| Active, not recruiting |
NCT01074021 -
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03890185 -
Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC
|
Phase 2 | |
| Not yet recruiting |
NCT04158414 -
Applying PET/MR in Oncology - a Prospective Project
|
N/A | |
| Completed |
NCT03656250 -
Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI
|
||
| Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|
||
| Recruiting |
NCT04476641 -
A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors
|
Phase 2 | |
| Terminated |
NCT03144661 -
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT06414577 -
Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy
|
Phase 2 | |
| Recruiting |
NCT03003182 -
A Study of Nasopharyngeal Carcinoma From Guangdong
|
N/A | |
| Not yet recruiting |
NCT06349889 -
Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma
|
Phase 2 | |
| Completed |
NCT01094405 -
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT05305131 -
Phase II Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer
|
Phase 2 | |
| Completed |
NCT01800071 -
A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
|
Phase 1 | |
| Recruiting |
NCT00304694 -
Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients
|
N/A | |
| Recruiting |
NCT05638269 -
A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
|